Ossio, an orthopedic medical device company, has announced it has raised $50.0 million in new funding. Founded in Israel in 2014, Ossio aims to transform the orthopedic experience for physicians, patients, and payors. This capital infusion is intended to support the company's mission to establish a new standard of care in the orthopedic fixation market.
The company's core innovation is OSSIOfiber™, a breakthrough material platform designed to replace traditional metal implants. Ossio targets the $10 billion-plus orthopedic fixation market, which includes screws, pins, and plates. OSSIOfiber™ provides orthopedic and podiatric surgeons with a biologically friendly alternative that restores mobility without leaving permanent material behind. The technology offers the mechanical strength required for secure fixation and easy insertion, while simultaneously enabling the body to regrow bone, completely incorporating and replacing the implant. This process is designed to avoid the adverse inflammation and weakness often associated with other bio-resorbable materials.
This funding round is significant for Ossio as it seeks to accelerate its strategic objectives. The company plans to use the newly secured capital to further its growth initiatives, which include expanding its commercialization efforts and supporting ongoing product development. The investment underscores confidence in Ossio's technology and its potential to disrupt the orthopedic implant sector by offering a more advanced solution for bone regeneration and fixation.
Looking ahead, Ossio is positioned to continue its expansion within the orthopedic market. The company's focus remains on advancing its OSSIOfiber™ platform to provide surgeons and patients with innovative options that improve outcomes and enhance the recovery process, ultimately aiming to redefine the standard for orthopedic fixation globally.
.png&w=3840&q=75)
